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Abstract 
Background: Topical photodynamic therapy (PDT) is an established treatment modality for 
various dermato-oncologic conditions. In Europe, initially requiring irradiation with red light, 
PDT of actinic keratosis (AK) can now also be carried out with exposure to daylight that has 
been clinically proven to be as effective as and less painful than red light. 
Objectives: In this paper, we propose a comparison between the conventional protocol for 
Aktilite CL 128 (red light source) PDT and the European consensus protocol for daylight 
PDT — with the exposure is assumed to be performed during either a clear sunny day or an 
overcast day — in the treatment of AK with methyl aminolevulinate through a mathematical 
modeling. 
Method: This already published modeling that is based on an iterative procedure alternating 
determination of the local fluence rate and updating of the local optical properties enables to 
estimate the local damage induced by the therapy. 
Results: The European consensus protocol for daylight PDT during a sunny day and an 
overcast day provides, on average, 6.50 and 1.79 times higher PDT local damages at the end 
2 
 
of the treatment than those obtained using the conventional protocol for Aktilite CL 128 PDT, 
respectively. 
Conclusions: Results analysis shows that, even performed during an overcast day, the 
European consensus protocol for daylight PDT leads to higher PDT local damages than the 
efficient conventional protocol for Aktilite CL 128. 
 
Keywords: Photodynamic therapy; local damage comparison; mathematical modeling; 
red light; daylight; Aktilite CL 128. 
 
I. Introduction 
 
Photodynamic therapy (PDT) is a cancer treatment combining a light of an appropriate 
wavelength, a photosensitizer (PS), and sufficient molecular oxygen to generate reactive 
oxygen species and destroy (pre-) malignant cells [1]. Over the last 15 years, topical PDT 
using 5-aminolevulinic acid (ALA) (ALA-PDT) or methyl aminolevulinate (MAL) (MAL-
PDT) has proven to be successful in the treatment of various dermatological conditions 
including actinic keratoses (AK) [2-6]. Topical administration of ALA or MAL leads to the 
selective accumulation of the photosensitizer protoporphyrin IX (PpIX) in the AK lesions and 
subsequent light irradiation leads to the destruction of the lesions. 
 
Red light irradiation with the Aktilite CL 128 lamp (Galderma SA, Lausanne, Switzerland) 
using a total light dose of 37 J/cm
2
 after three hours of incubation with MAL, is a 
conventional protocol that is approved and widely used in Europe for the PDT treatment of 
AK. This protocol, referred to in this paper as the conventional protocol for Aktilite CL 128 
PDT, has been demonstrated to be an effective treatment with similar efficacy and better 
cosmetic results compared with standard therapies [7]. However, due in particular to high pain 
scores reported by patient during the treatment [8] and high room occupancy for 
dermatologists, many other protocols for PDT involving either shorter incubation times [9], 
lower fluence rates [10], irradiation with other light sources [11]… have been proposed for 
dermatological PDT. 
 
Among these alternative PDT protocols, several protocols involving exposure with daylight 
instead of irradiation with the Aktilite CL 128 lamp have been investigated over the last 
decade[11-16]. Most of these protocols involve an incubation with MAL for a maximum of 
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30 minutes followed by a daylight exposure for between 1.5 and 2.5 hours. From an European 
consensus [14], using a two hours daylight exposure within 30 minutes after MAL application 
leads to a protocol, hereinafter referred to as the European consensus protocol for daylight 
PDT, as effective as and better tolerated by patients than the conventional protocol for Aktilite 
CL 128 PDT. The European consensus protocol for daylight PDT, more manageable in 
clinical practice than the conventional protocol for Aktilite CL 128 PDT [11], has been 
recently approved in Europe for the treatment of thin, non-hyperkeratotic AK [17]. Based on 
the two comparative clinical studies between a protocol for daylight PDT and the 
conventional protocol for Aktilite CL 128 PDT [11,16], we set the incubation time for the 
European consensus protocol for daylight PDT to 30 minutes. 
 
In this paper, we propose to compare the efficiency of the conventional protocol for Aktilite 
CL 128 PDT (light source: Aktilite CL 128, incubation time: three hours, light dose: 37 
J/cm
2
) to the one of the European consensus protocol for daylight PDT (light source: daylight, 
incubation time: 30 minutes, treatment duration: two hours) through a mathematical modeling 
already published in our previous works [18,19]. Two weather conditions for the European 
consensus protocol for daylight PDT have been considered for this comparison: a clear sunny 
day and an overcast day. The mathematical modeling that involves a logistic model for both 
the biological clearance of PpIX and the conversion of MAL into PpIX and an analytic model 
for the PpIX photobleaching enables the local damage induced by the therapy to be estimated 
[19]. 
 
A detailed description of both the conventional protocol for Aktilite CL 128 PDT and the 
European consensus protocol for daylight PDT is presented in Section II while Section III 
describes the mathematical modeling enabling the quantification of the PDT local damage. 
The PDT local damages achieved by the conventional protocol for Aktilite CL 128 PDT, the 
European consensus protocol for daylight PDT during a sunny day and the European 
consensus protocol for daylight PDT during an overcast day are compared in Section IV. 
Based on the comparison results, some discussions and conclusions are drawn in Section V. 
 
II. The two topical PDT protocols considered in this paper 
 
Incubation time here refers to the time elapsed between the application of MAL cream and the 
beginning of the light irradiation. 
4 
 
 
A. The conventional protocol for Aktilite CL 128 PDT 
 
The Aktilite CL 128 lamp (Galderma SA, Lausanne, Switzerland) is the most widely used 
device system for topical PDT in Europe. Equipped with 128 light emitting diodes (LEDs) 
arranged in a 8×16 array, this lamp emits red light with a fluence rate of 70-100 mW/cm
2
 (at a 
distance from 5 cm to 8 cm) [20], a peak wavelength of 632 nm [21] and a full width at half 
maximum (FWHM) of approximately 19 nm [21]. The fluence can be adjusted at the control 
panel of the lamp and the irradiation time is calculated automatically accordingly: for the 37 
J/cm
2
 as recommended for dermatological MAL-PDT, the irradiation time varies between 6 
and 10 minutes. Moreover, with an irradiation field size of 8×18 cm, the Aktilite CL 128 lamp 
enables quite large fields to be treated. 
 
Sequentially involving gentle curettage of the lesions, MAL cream application with occlusive 
dressing to each lesion and 5 mm of surrounding tissue for an incubation time of three hours, 
removal of excess MAL cream, positioning of the Aktilite CL 128 lamp head 5-8 cm over the 
area to be treated and irradiation with a total light dose of 37 J/cm
2
, the so called conventional 
protocol for Aktilite CL 128 PDT has proven to be effective for the treatment of various skin 
malignancies [22-27] including actinic keratosis [7,28-30]. With similar response rates 
compared with standard therapies in the treatment for AK, the conventional protocol for 
Aktilite CL 128 PDT has also demonstrated improved cosmetic outcomes [7,8]. 
 
B. The European consensus protocol for daylight PDT 
 
Many studies on daylight PDT for the treatment of AK [11-16,31-34] have been published 
since the early work of Wiegell et al. [11]. 
As stated above, the fundamental difference between the protocols for daylight PDT and the 
protocols for Aktilite CL 128 PDT is the exposure to daylight in place of the red light 
provided by the Aktilite CL128 lamp. 
Furthermore, most of the studies on daylight PDT report an incubation with MAL cream for a 
maximum of 30 minutes and no excess cream removal before exposure to daylight. The 
combination of these two factors involves, during all the procedure, an accumulation of PpIX 
greatly reduced compared to that of the protocols for Aktilite CL 128 PDT. In fact, the 
incubation time prior to the daylight exposure that is shorter than the usual three hours used 
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for the protocols for Aktilite CL 128 PDT, results in a low initial PpIX accumulation. 
Thereafter, without excess cream removal and with a fluence rate lower than the one of the 
Aktilite CL 128 lamp, the protocols for daylight PDT allows for a balance between the 
development and the photodegradation of PpIX (the PpIX molecules are photoactivated / 
photodegraded as quickly they are formed) thus ensuring the maintain of a low PpIX 
accumulation. 
Another difference between the protocols for daylight PDT and the protocols for Aktilite CL 
128 PDT is the application of a chemical sunscreen to the treatment area to prevent sunburn. 
This sunscreen allowing wavelengths activating PpIX to pass through is usually applied 
before the gentle curettage of the lesions [13,15,34]. 
 
Among the studies on daylight PDT, two randomized clinical trials each compared a protocol 
for daylight PDT with the conventional protocol for Aktilite CL 128 PDT [11,16]. With an 
exposure to daylight PDT of 2.5 hours and 2 hours for the first clinical trial [11] and the 
second one [16], respectively, the two involved protocols for daylight PDT (both with 30 
minutes incubation time with MAL) have been demonstrated as effective as the conventional 
protocol for Aktilite CL 128 PDT. Furthermore, due to the above mentioned reduction in 
PpIX accumulation obtained with the protocols for daylight PDT, patients enrolled in these 
two trials reported less pain during the protocols for daylight PDT than during the 
conventional protocol for Aktilite CL 128 PDT [11,16]. This experience of a nearly pain-free 
treatment for patients has also been reported in other studies on daylight PDT [12-15,32-34]. 
Finally, with a shorter time of clinic attendance than the conventional protocol for Aktilite CL 
128 PDT, the protocols for daylight PDT are more convenient for both patients and clinicians. 
 
With a maximum of 30 minutes of MAL incubation and no excess cream removal before 
daylight exposure for 2 hours, the so called European consensus protocol for daylight PDT 
has been adopted from a European consensus in 2012 [14]. Based on the above mentioned 
randomized clinical trials [11,16], we set the incubation time for the European consensus 
protocol for daylight PDT to 30 minutes. 
 
In this study, the outdoor temperature was assumed to be sufficient for the PDT process to 
occur [31,35] and thus no further consideration has been given to the temperature in this 
paper. 
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III. Mathematical modeling for topical PDT protocol 
 
A. AK sample model 
 
To account for both the confinement of AKs to the epidermis and the usual 100 μm thickness 
of epidermis [36], the simplified AK sample model consists of a 10 µm wide and 100 μm 
thick parallelepiped (Figure 1). The AK tissue is assumed homogeneous and its optical 
properties are set to the values reported in Garcia-Uribe et al. [37]. 
A primary planar beam with fluence rate 0S  is assumed to perpendicularly irradiate the 
surface of the AK sample model as illustrated in Figure 1. 
 
 
Figure 1: The AK sample model 
 
B. Models for the different fluence rates 
 
As depending on the weather conditions [31,38,39], the spectral fluence rate for the daylight 
is not unique. In this paper, two spectral fluence rates have been used: the first one 
7 
 
corresponds to a clear sunny day (blue curve in Figure 2) while the second stands for an 
overcast day (cyan curve in Figure 2). These two spectral fluence rates were recorded in the 
study of O’Gorman et al. [39], who kindly provided them to us. The use of these two spectral 
fluence rates for the daylight aims to quantify the effect of the weather conditions on the PDT 
local damage. 
 
Among the various spectral fluence rates for the Aktilite CL 128 lamp we have at our 
disposal, the one measured at a distance of 8 cm from the lamp by O’Gorman et al. [39] (red 
curve in Figure 2) was preferred. Indeed, recorded using the same measurement system as the 
two spectral fluence rates for daylight, this spectral fluence rate seems to be the most 
appropriate for a pertinent comparison. 
 
 
Figure 2: The spectral fluence rate for the Aktilite CL 128 lamp, the sunny daylight and the 
overcast daylight, respectively. All these three spectral fluence rates were provided by the 
authors of [39]. 
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C. Modeling of the PDT process 
 
The modeling method is the same as in our previously validated work [19] and therefore only 
outlines are referred to in this paper without further discussion. 
 
Let the incubation start at time st 0  and let the light irradiation be performed during the time 
interval  endstart tt , : 
 3startt  hours and ttt startend   ( t  is the irradiation time necessary to achieve the 
recommended 37 J/cm
2
 using the spectral fluence rate for the Aktilite CL 128 lamp 
depicted in Figure 2) for the conventional protocol for Aktilite CL 128 PDT, 
 5.0startt  hours and s 7200 startend tt  for the European consensus protocol for daylight 
PDT. 
 
Based on our previous works [18,19], the modeling of the PDT process consists of two steps 
that are iteratively repeated: determination of the local fluence rate and updating of the PpIX 
absorption coefficient. 
 
1. Determination of the fluence rate 
 
The local total fluence rate at time t , depth z  and wavelength  , denoted by   ,, zt , is 
given by equation 1 [18,19,40]: 
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Where: 
 The above defined 0S  is the spectral fluence rate of the primary planar broad beam, 
 Due to the accumulation of PpIX in AK lesions, the total absorption coefficient, a , is the 
sum of the PpIX absorption coefficient, PpIXa , , and the actinic keratosis absorption 
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coefficient, AKa , , 
 The total transport coefficient, t , is the sum of the total absorption coefficient, a , and 
the actinic keratosis reduced scattering coefficient, AKs, , 
 The effective attenuation coefficient, eff , is equal to ta 3 , 
 The two parameters, b  and P , depending on both the optical properties of the actinic 
keratosis and the boundary conditions at the actinic keratosis surface, are computed as 
described in [40]. 
 
2. Updating of the PpIX absorption coefficient 
 
The updating formula for the PpIX absorption coefficient in an unit volume, UV , is expressed 
as follows (equation 2) [18,19]: 
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(2) 
Where: 
 dt  is the time increment, 
  PpIX  is the PpIX molar extinction coefficient for wavelength  , 
  ,  and c  are the Avogadro number (6.022×1023 /mol), the Planck constant 
(6.626×10
34
 J×s) and the speed of light (3×10
8
 m/s), respectively, 
 L , k ,   and   are the parameters of the depth-dependent logistic growth related to both 
the biological clearance of PpIX and the conversion of 5-ALA into PpIX (2
nd
 term in the 
right hand side) [19], 
   and  ~  are the bimolecular rate constant for the reaction of singlet oxygen with PpIX 
and the singlet oxygen quantum yield, respectively. These two parameters allow the 
photobleaching process to be analytically modeled (3
rd
 term in the right hand side) [19]. 
 
3. Iterative procedure 
 
All the involved parameters were assigned to the values reported in our previous work and 
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empirically determined in the literature [18,19] (Table 1). Assuming the initial distribution for 
the PpIX absorption coefficient reported in the last row in Table 1, equation 1 enables the 
local total fluence rate at time 0,     ,,,0 zz , to be calculated. Applying equation 2 then 
yields the distribution for the PpIX absorption coefficient at time dt ,   


,,
,,
zPpIXa
zdt , to 
be deduced. By iterating equations 1 and 2, all the PpIX absorption coefficients and local total 
fluence rates can be determined throughout the treatment. 
 
Parameters Value 
dt  1×10
-5
 s 
k  2.93×10
-4
 /s 
  1.01×104 s 
  0.89 /mm 
L  11.8 pmol/ml     h3exp1 kVU  
  5.3×10
9
 l/mol/s 
  0.56 
  ,,0, zPpIXa  
   
 




 k
zL
VU
PpIX
exp1
exp
 
Table 1: Specification of the model parameters from [19] 
 
D. Quantification of the PDT local damage 
 
The integral in the last part of the right hand side of equation 2 represents the number of 
singlet oxygen molecules generated during the time interval  dttt ;  in an unit volume, UV , 
located at depth z  in the AK sample model when the PpIX molecules, excited by absorption 
of photons, return to the ground state. Summing this integral over the time intervals 
 dttt startstart ; ,  dttdtt startstart  2; , …,   dtitdtit startstart  ;1  provides the total 
cumulative singlet oxygen molecules produced during the time interval  dtitt startstart ; . 
From several studies on PDT [40,41], this cumulative quantity enables the quantification of 
the PDT local damage, D , over time (equation 3). 
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IV. Results 
 
A. Comparison in terms of effective fluence 
 
Given the spectral fluence rate for the Aktilite CL 128 lamp (Figure 2), several parameters 
have been computed (Table 2). First, from the integration of this spectrum over wavelength, 
the fluence rate has been estimated to be 85.39 mW/cm
2
 that is consistent with the above-
mentioned 70-100 mW/cm
2
 range provided by the manufacturer. By considering this fluence 
rate, the fluence of 37 J/cm
2
 of the conventional protocol for Aktilite CL 128 PDT is achieved 
using an irradiation time of 433.3 seconds (Table 2). Moreover, weighting the spectral fluence 
rate with the normalized absorption spectrum for PpIX, which is derived from data measured 
by the Research Center for Automatic Control of Nancy (CRAN) (Figure 3.a), enables the 
effective or PpIX-weighted spectral fluence rate to be obtained (Figure 3.a) and the effective 
fluence rate to be deducted by integration over wavelength (approximately, 1.44 mW/cm
2
) 
[11,39] (Table 2). Multiplying the effective fluence rate by the above determined irradiation 
time of 433.3 seconds leads to an effective fluence of 0.63 J/cm
2
 for the conventional protocol 
for Aktilite CL 128 PDT. 
 
Similar computations have been carried out for the sunny daylight spectral fluence rate and 
the overcast daylight spectral fluence rate (Figure 2). The integration over wavelength of 
these two spectral fluence rates yields fluence rates of 55.2 mW/cm
2
 and 7.75 mW/cm
2
 for the 
sunny daylight and the overcast daylight, respectively (Table 2). The effective or PpIX-
weighted spectral fluence rate for the sunny daylight (respectively, the overcast daylight), 
which was obtained by weighting the spectral for the sunny daylight fluence rate 
(respectively, the overcast daylight fluence rate) with the normalized absorption spectrum for 
PpIX, yields, when integrated over wavelength, an effective fluence rate of 5.11 mW/cm
2
 
(respectively, 0.80 mW/cm
2
) for the sunny daylight (respectively, the overcast daylight) 
(Table 2, Figure 3.b and 3.c). Using an exposure of 2 hours as required with the European 
consensus protocol for daylight PDT, the sunny daylight fluence rate (respectively, the 
effective sunny daylight fluence rate) leads to a fluence of 397.44 J/cm
2
 (respectively, an 
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effective fluence of 36.79 J/cm
2
) while the overcast daylight fluence rate (respectively, the 
effective overcast daylight fluence rate) provides a fluence of 55.8 J/cm
2
 (respectively, an 
effective fluence of 5.76 J/cm
2
). 
 
From these computations performed using a homemade software available online [42], the 
effective fluence achieved using the European consensus protocol for daylight PDT during a 
sunny day is 58.40 and 6.40 times higher than those achieved using the conventional protocol 
for Aktilite CL 128 PDT and the European consensus protocol for daylight PDT during an 
overcast day, respectively. The effective fluence obtained using the European consensus 
protocol for daylight PDT during an overcast day is also — although to a lesser extent than 
the European consensus protocol for daylight PDT during a sunny day — higher (9.13 times 
higher) than that obtained using the conventional protocol for Aktilite CL 128. 
 
 
 
a 
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b 
 
c 
Figure 3: The spectral fluence rate (green curves) and the effective spectral fluence rate (red 
curve in a), blue curve in b) and cyan curve in c)) for a) the Aktilite CL 128 lamp at a distance 
of 8 cm from the lamp, b) the sunny daylight and c) the overcast daylight are scaled according 
to the left axis while the normalized absorption spectrum for PpIX (black curve) is plotted 
according to the right axis (Note: left axes in (b) and (c) are identically scaled whereas a 
different scale is applied for (a) due to its much higher amplitude). All the three spectral 
fluence rates were provided by the authors of [39]. 
 
Light source 
Aktilite 
CL128 
Sunny 
daylight 
Overcast 
daylight 
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lamp 
Incubation time in h 3 0.5 0.5 
Irradiation time in s 433.3 7200 7200 
Fluence rate in mW/cm
2
 85.39 55.2 7.75 
Fluence in J/cm
2
 (product of the irradiation time in 
s and the fluence rate in W/cm
2
) 
37 397.44 55.8 
Effective or PpIX-weighted fluence rate in 
mW/cm
2
 
1.44 5.11 0.80 
Effective fluence in J/cm
2
 (product of the 
irradiation time in s and the effective fluence rate 
in W/cm
2
) 
0.63 36.79 5.75 
Table 2: Standard (row 4) and effective (row 6) fluence rates for the Aktilite CL128 lamp 
(second column), the sunny daylight (third column) and the overcast daylight (fourth column) 
computed from the spectral fluence rate provided by [39]. The irradiation times used in this 
paper (row 3) and the corresponding standard and effective fluences are also indicated (rows 5 
and 7). 
 
B. Comparison in terms of photodynamic dose 
 
All the computations were performed using a Matlab™ program on a standard personal 
computer (Intel Xeon CPU E3-1240 V2 3.40 GHz–8Go of RAM–Windows 7 64 bits). 
 
The PDT local damages obtained using the conventional protocol for Aktilite CL 128 PDT, 
the European consensus protocol for daylight PDT during a sunny day and the European 
consensus protocol for daylight PDT during an overcast day are displayed as a function of 
depth in Figure 4 and as a function of time in Figure 5. 
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Figure 4: Evolution in depth of the PDT local damage achieved at the end of the treatment 
using the conventional protocol for Aktilite CL 128 PDT (red curve), the European consensus 
protocol for daylight PDT during a sunny day (blue curve) and the European consensus 
protocol for daylight PDT during an overcast day (cyan curve). 
 
From Figure 4, whatever the depth position in the AK sample model (Figure 1), the PDT local 
damage achieved at the end of the treatment using the European consensus protocol for 
daylight PDT during a sunny day is on average about 6.50 and 3.63 times higher than those 
achieved at the end of the treatment using the conventional protocol for Aktilite CL 128 PDT 
and using the European consensus protocol for daylight PDT during an overcast day, 
respectively. The ratio between the PDT local damage obtained using the European consensus 
protocol for daylight PDT during an overcast day and the one obtained using the conventional 
protocol for Aktilite CL 128 PDT is approximately 1.80 at 0 µm depth and 1.77 at 100 µm 
depth. 
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Figure 5: Evolution in time of the PDT local damage achieved using the conventional 
protocol for Aktilite CL 128 PDT (red curves), the European consensus protocol for daylight 
PDT during a sunny day (blue curves) and the European consensus protocol for daylight PDT 
during an overcast day (cyan curves). The bright solid curves (respectively, light dashed 
curves) represent the PDT local damages at 0 µm (respectively, at 100 µm) in depth in AK. 
 
From Figure 5, for the European consensus protocol for daylight PDT, the shape of the time 
courses of the PDT local damage tends to demonstrate an exponential trend (blue and cyan 
curves in Figure 5) while that for the conventional protocol for Aktilite CL 128 PDT suggests 
a very slight logarithmic trend (red curves). This results that, at least over the considered time 
intervals, the PDT local damage produced using the conventional protocol for Aktilite CL 128 
PDT increases in time much faster than those produced using the European consensus 
protocol for daylight PDT (Figure 5). 
 
C. Comparison in terms of number of PpIX molecules 
 
The evolution of the number of PpIX molecules present in an unit volume, UV , at time t  and 
depth z , deduced from equation 4, is illustrated for the conventional protocol for Aktilite CL 
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128 PDT, the European consensus protocol for daylight PDT during a sunny day and the 
European consensus protocol for daylight PDT during an overcast day in Figure 6. 
   
 

PpIX
U
PpIXaPpIX
V
ztztM

 ,,, ,  (4) 
 
 
Figure 6: Evolution in time of the number of PpIX molecules present at 50 μm in depth in AK 
using the conventional protocol for Aktilite CL 128 PDT (red curve), the European consensus 
protocol for daylight PDT during a sunny day (blue curve) and the European consensus 
protocol for daylight PDT during an overcast day (cyan curve). 
 
From Figure 6, regarding the conventional protocol for Aktilite CL 128 PDT, the irradiation 
(starting at time=10800 s) leads to a mean percent drop of 35.24% in the number of PpIX 
molecules while the number of PpIX molecules corresponding to the European consensus 
protocol for daylight PDT during an overcast day continues to increase even after the 
beginning of irradiation (occurring at time 1800 seconds). For the European consensus 
protocol for daylight PDT during a sunny day, the irradiation results, in terms of the number 
of PpIX molecules, in a transient slight decrease followed by a further controlled increase. 
 
Furthermore, an important number of PpIX molecules is still present at the end of the 
irradiation for the conventional protocol for Aktilite CL 128 PDT and the European consensus 
protocol for daylight PDT during an overcast day (Figure 6). With regard to the European 
consensus protocol for daylight PDT during a sunny day, the number of PpIX molecules 
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present at the end of the irradiation is slightly higher than that at the beginning of irradiation. 
 
V. Discussion 
 
In this paper, a comparison between the two most widely used MAL-PDT protocols in Europe 
for the treatment of actinic keratosis (AK) is performed using a mathematical modeling of the 
PDT process: 
 The conventional protocol for Aktilite CL 128 PDT (light source: Aktilite CL 128, 
incubation time: three hours, light dose: 37 J/cm
2
) [7,8,29], 
 The European consensus protocol for daylight PDT (light source: daylight, incubation 
time: 30 minutes, treatment duration: two hours) [14]. 
Two weather conditions for the European consensus protocol for daylight PDT have been 
considered for this comparison: a clear sunny day and an overcast day. The spectral fluence 
rates for the Aktilite CL 128, the clear sunny daylight and the overcast daylight have been 
provided by the authors of O’Gorman et al. [39] (Figure 2). 
 
The comparison is performed using an AK sample model consisting of a 100 μm thick 
parallelepiped (Figure 1) and a recently published modeling of the PDT process iteratively 
alternating determination of the fluence rate and updating of the optical properties [18,19]. 
The determination of the fluence rate involves solving the one-dimensional diffusion equation 
(equation 1, [18,19]) while the updating of the optical properties takes the biological clearance 
of PpIX, the conversion of MAL into PpIX and the PpIX photobleaching into account 
(equation 2, [19]). All the parameters involved in equations 1 and 2 are set to published 
empirical values, which were obtained with PpIX and with either normal human epidermis or 
AK (Table 1, [18]). The updating formula (equation 2) explicitly provides the number of 
singlet oxygen molecules produced at each iteration (integral in the right hand side). 
Cumulating this number over the irradiation time enables the quantification of the PDT local 
damage (equation 3, [18,19]). 
 
Applying to the conventional protocol for Aktilite CL 128 PDT, to the European consensus 
protocol for daylight PDT during a sunny day and to the European consensus protocol for 
daylight PDT during an overcast day, the model allows evaluation and comparison of their 
performance in terms of the PDT local damage. A comparison has also been performed in 
terms of effective or PpIX-weighted fluence. 
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From the results, regardless the two weather conditions considered in this study, the European 
consensus protocol for daylight PDT is more efficient in terms of both effective fluence and 
PDT local damage than the conventional protocol for Aktilite CL 128 PDT. First, this finding 
underlines the relevance of the European consensus protocol for daylight PDT, even when 
performed during an overcast day. Then this finding supports the non-inferiority in efficacy of 
the European consensus protocol for daylight PDT compared to the conventional protocol for 
Aktilite CL 128 PDT that has been demonstrated by a clinical trial, including all weather 
conditions except rain or cold [16]. This finding also suggests that, although a minimum 
effective fluence of 8 J/cm
2
 is recommended with daylight PDT to result in an effective 
treatment of AK [12,31], the effective fluence of 5.75 J/cm
2
 related to the overcast day 
considered in this study (Table 2), is sufficient for the European consensus protocol for 
daylight PDT to perform better than the efficient conventional protocol for Aktilite CL 128 
PDT. Finally, based on the well-known efficiency of the conventional protocol for Aktilite CL 
128 PDT, this finding could reflect a potential over-treatment of the lesions when using the 
European consensus protocol for daylight PDT during a sunny day but also during an overcast 
day. 
 
As already mentioned in many studies on daylight PDT [12,13,15,31,39] and as evidenced by 
the above mentioned values, the effective fluence varies depending on weather conditions. 
This dependence on weather conditions is also evident here in terms of the PDT local damage: 
the better the weather conditions, the more efficient is the European consensus protocol for 
daylight PDT. Nonetheless, based on the studies of Wiegell et al. [12,31] and O’Gorman et al 
[39] that have found no association between response rate and effective fluence in patients 
who received an effective fluence with daylight PDT higher than 8 J/cm
2
 and 3.2 J/cm
2
, 
respectively, a sunny day is not necessarily required for the European consensus protocol for 
daylight PDT to be effective (an overcast daylight may be sufficient for the European 
consensus protocol for daylight PDT to destroy any cancer cells). This has also been 
highlighted by Rubel et al. [16], which have reported that, although patients received variable 
effective fluences during the European consensus protocol for daylight PDT, no correlation to 
efficacy was found. These clinical results with similar response rates whatever the weather 
conditions (except rainy or cold conditions) tend to support the above suggested hypothesis of 
overtreatment of the lesions by the European consensus protocol for daylight PDT. 
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The information provided by the ratios between the effective fluences is consistent with that 
provided by the ratios between the PDT local damages. In fact, if a ratio between two 
considered effective fluences is higher than 1, then the ratio between the two corresponding 
PDT local damages is also higher than 1. Nonetheless, the ratios between the effective 
fluences are always higher than those between the PDT local damages. This is explained, to a 
large extent, by the fact that the effective fluence is computed using the normalized absorption 
spectrum for PpIX (Figure 3) whereas the PDT local damages involves the “actual” 
absorption spectrum for PpIX. With an incubation time longer than that for the European 
consensus protocol for daylight PDT, the conventional protocol for Aktilite CL 128 PDT 
leads to a higher initial PpIX accumulation (Figure 6) and subsequently to a higher initial 
absorption spectrum for PpIX. This in turn allows to partially offset the higher effective 
fluence rate for the European consensus protocol for daylight PDT in the iterative calculation 
of the PDT local damage (equations 1-3). In contrast, as the effective fluence is computed 
from the normalized PpIX absorption spectrum, no such offset is present and thus the 
information provided by the effective fluence might not be sufficient to predict the result of 
the MAL-PDT procedure. The PDT local damage, as defined in this paper, may therefore be a 
more appropriate predictor… 
 
Regarding the evolution in time of the PDT local damage (Figure 5), with an effective fluence 
rate about 3.55 times lower than that of the European consensus protocol for daylight PDT 
during a sunny day (Table 2), the conventional protocol for Aktilite CL 128 PDT, however, 
leads to a higher increase rate for the PDT local damage. This results from the above 
mentioned longer incubation time and subsequent higher initial PpIX absorption coefficient 
for the conventional protocol for Aktilite CL 128 PDT compared to the European consensus 
protocol for daylight PDT, leading to a higher initial photons absorption efficiency (equations 
1-3). 
 
From Figure 6, the beginning of the irradiation is clearly identifiable for the conventional 
protocol for Aktilite CL 128 PDT with a more than 30 percent drop in the number of PpIX 
molecules resulting from the above mentioned high initial photons absorption efficiency. On 
the contrary, the steady growth curve observed for the European consensus protocol for 
daylight PDT during an overcast day makes the identification of the beginning of the 
irradiation impossible: the 0.80 mW/cm
2
 effective fluence rate combined with a low initial 
PpIX accumulation do not allow a photobleaching of the PpIX molecules important enough to 
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outweigh the conversion of MAL into PpIX. Regarding the European consensus protocol for 
daylight PDT during a sunny day, despite the low initial PpIX accumulation, the 5.11 
mW/cm
2
 effective fluence rate appears to be appropriate for maintaining approximately 
constant the number of PpIX molecules. 
 
Consideration also needs to be given to the important number of PpIX molecules still present 
at the end of the conventional protocol for Aktilite CL 128 PDT (Figure 6). This important 
number tends to demonstrate that the incubation time or the cream concentration in MAL for 
this protocol could be reduced [43]. This observation can be extended to the European 
consensus protocol for daylight PDT during an overcast day… 
 
The overall results emphasize the need to refine the parameters of both the conventional 
protocol for Aktilite CL 128 PDT and the European consensus protocol for daylight PDT. 
This refinement (reduction of the incubation time, reduction of the irradiation time…) would 
allow for a similar efficiency but an improved tolerability and a more manageable clinical 
practice. 
 
Only two weather conditions for the European consensus protocol for daylight PDT have been 
studied in this paper. These two weather conditions have been chosen because their spectral 
fluence rates discussed in the study of O’Gorman et al. [39] have been kindly provided by the 
authors. Any other weather condition with an available spectral fluence rate could obviously 
be investigated using the same mathematical modeling… The subsequent results will either 
support the above suggested hypothesis of overtreatment of the lesions by the European 
consensus protocol for daylight PDT, or will allow to estimate the PDT local damage at which 
the treatment becomes effective. 
In this study, the temperature was, as above mentioned, assumed to be at least 10°C so that 
the PDT process to occur [31,35]. If this is not the case, or if it's raining or windy, a 
greenhouse may be used [44]. However, the spectral fluence rate of the daylight is modified 
by the filtering effect of the greenhouse glass, and the mathematical modeling proposed in this 
paper could be used to quantify this filtering effect in terms of the PDT local damage. Another 
solution to get rid of this dependence on the weather conditions, geographical location, 
seasons…, is to use a light source with a spectral fluence rate close to that of daylight [39,44]; 
a comparative study of these light sources for “indoor” daylight PDT could also be performed 
in terms of the PDT local damage as defined in this paper. 
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VI. Conclusion 
 
In this paper, we have compared the conventional protocol for Aktilite CL 128 PDT (light 
source: Aktilite CL 128, incubation time: three hours, light dose: 37 J/cm
2
) with the European 
consensus protocol for daylight PDT (light source: daylight, incubation time: 30 minutes, 
treatment duration: two hours). This comparison performed in terms of the effective fluence 
and the PDT local damage tends to demonstrate, whatever the two weather conditions 
considered for this comparison (i.e., a clear sunny day and an overcast day) the European 
consensus protocol for daylight PDT perform better than the conventional protocol for 
Aktilite CL 128 PDT. 
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